Celldex Phase 2 barzolvolimab in EoE meets primary endpoint but no clinical benefit; advancement stopped

Celldex Therapeutics, Inc.

Primary endpoint met: peak mast cell count reduced by -36.0 vs placebo -2.7 (p<0.0001) at Week 12.
No improvement in Dysphagia Symptom Questionnaire (DSQ) (p=0.33) or endoscopic EREFS score (p=0.95).
Company will not advance barzolvolimab in EoE; safety profile favorable at 300 mg Q4W.
Pipeline continues in chronic spontaneous urticaria, atopic dermatitis, prurigo nodularis, and inducible urticaria.
Full study (28-week treatment, 44-week total) outcomes consistent with 12-week results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.